Sarepta Therapeutics Annual Income Statement (NASDAQ:SRPT)

Add to My Stocks
$30.38 $1.7 (5.93%) SRPT stock closing price Feb 22, 2017 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Sarepta Therapeutics stock price. The income statement gives the investor an understanding of the topline and bottomline numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for SRPT which implies a YoY revenue decline of $8.5M is specific to a period of time. Investors typically check YoY or QoQ revenue growth. 2015 revenue is $1.25M and has decreased from $9.75M year on year as is evident when you compare the latest figures in the latest Sarepta Therapeutics profit and loss statement with those of the prior corresponding period. (See also:Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow) Sarepta Therapeutics revenue for 2015 is $1.25M. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Sales or Revenues
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M
Cost Of Goods Sold (COGS)---------
Sarepta Therapeutics Gross Profit
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M
Research & Development Expense146.39M94.23M72.9M52.4M66.86M35.97M24.39M38.91M34.76M
Selling General & Admin Expense75.04M49.31M31.59M14.63M16.05M14.38M8.69M9.79M9.33M
Income Before Depreciation Depletion Amortization-220.18M-133.78M-90.28M-29.7M-35.92M-20.93M-15.5M-27.45M-33.1M
Depreciation Depletion Amortization---------
Non Operating Income0.15M-2M-21.7M-91.58M33.6M-11.24M-9.65M3.5M5.93M
Interest Expense---------
Sarepta Therapeutics Pretax Income
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Provision for Income Taxes---------
Minority Interest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Extraordinary Items & Discontinued Operations---------
Sarepta Therapeutics Net Income (Profit/Loss)
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Average Shares used to compute Diluted EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Average Shares used to compute Basic EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Income Before Nonrecurring Items-220.03M-133M-89.19M-29.35M-2.32M-32.17M-25.16M-23.95M-27.17M
Income from Nonrecurring Items--2.79M-22.79M-91.94M-----
Sarepta Therapeutics Earnings Per Share Basic Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00
Sarepta Therapeutics Earnings Per Share Diluted Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00
EPS Diluted Before Nonrecurring Items-5.20-3.32-2.64-1.24-0.12-1.74-1.62-2.04-3.00
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common---------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

1:11
SRPT
Sarepta Therapeutics stock analysis involves checking at least a few of the important things like:
  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth (See: Sarepta Therapeutics revenue chart) implies that the company is growing, which has not been the case with Sarepta Therapeutics. One must stay away from stocks whose revenues are declining.
  • Bottom line: The Bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $1.25M - other expenses = $-220.03M for SRPT stock. An improving bottomline implies that the company is growing profits.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Sarepta Therapeutics historical stock prices to check how the price has moved with time. .